Peringkat dalam Saham
#28265
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to... Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
Kapitalisasi Pasar
$27.51M
Perubahan (1 tahun)
9.62%
Perdagangan Syntara Limited (SNT)
Pendapatan untuk Syntara Limited (SNT)
Pendapatan pada Aug 2026 TTM: 0
Menurut laporan keuangan terbaru dari Syntara Limited, pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Syntara Limited dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun |
Pendapatan |
Mengubah |
|
Tidak cukup data untuk tanggal yang disediakan. |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan |
Pendapatan |
Perbedaan Pendapatan |
Negara |
|
|
- |
-
|
DE
|
|
|
- |
-
|
DE
|
|
|
- |
-
|
JP
|
|
|
- |
-
|
CH
|
|
|
$6.61B |
-
|
IN
|
